Abstract 2701
Background
The basic scope of population-based cancer registries (CRs) is to collect data that enable computation of cancer incidence. In addition to this, nowadays most registries can provide more extensive information such as data on stage and treatment, which could be used to assess and compare different care pathways. The current analysis reports on treatment by stage patterns for female breast cancer in Europe.
Methods
Data from CRs included in the European Cancer Information System (ECIS) and having submitted data on stage and treatment for the ENCR-JRC project were analysed. Proportion of cases by treatment type: surgery (SG), radiotherapy (RT), systemic therapy (ST), by stage, age, period and region were calculated.
Results
829,247 cases from 20 CRs were analysed. Treatment for stage I (UICC TNM) patients aged 19-74 in 1999-2005 was SG alone (22%), SG+ST (13%) SG+RT (31%), SG+RT+ST (32%). SG alone decreased to 18%, while SG+RT+ST rose to 37% in 2006-13. High variability was observed: in Eastern Europe SG alone was 31%, SG+ST 17%, SG+RT 24%, SG+RT+ST 23% in 2006-13, in Western Europe SG alone was 12%, SG+ST 13%, SG+RT 31%, SG+RT+ST 43%. For age 75+ in 1999-2005 SG (37%) and SG+ST (20%) were higher than in 19-74 patients, while SG+RT (17%) and SG+RT+SG (15%) were lower. SG decreased to 31%, SG+RT+ST rose to 20% in 2006-13. Untreated patients were 3% in both periods. For the regional comparison, in 2006-13 SG alone was 50% in Eastern Europe vs 25% in Western Europe; SG+RT+ST was 9% in Eastern Europe, 24% in Western Europe. In 2006-13 for younger stage IV patients SG alone was 7%, ST alone 29%, SG+ST 18%, SG+RT+ST 14%, no treatment 9%. For 75+ patients SG was 11%, ST 30%, SG+ST 12%, SG+RT+ST 7%, no treatment 15%.
Conclusions
Variability in treatment patterns was observed by stage, age, period and region. Clinical information from CRs should be routinely used to monitor clinical care patterns, according to national and international recommendations, to compare levels of compliance and inform policy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
European Commission.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4317 - Prognostic factors analysis of 343 patients with adenocarcinoma of esophagogastric junction
Presenter: Yixun Lu
Session: Poster Display session 2
Resources:
Abstract
4099 - Effects of preoperative preparation time on efficacy of neoadjuvant chemotherapy (SOX) in patients with advanced gastric cancer
Presenter: Xinxin Wang
Session: Poster Display session 2
Resources:
Abstract
3769 - The prognostic value of higher absolute lymphocyte counts for patients with surgically resected non-advanced gastric cancer
Presenter: Se Jun Park
Session: Poster Display session 2
Resources:
Abstract
1718 - Trastuzumab and pertuzumab added to neoadjuvant chemoradiotherapy in resectable HER2+ esophageal adenocarcinoma patients: an update on survival and predictive biomarkers in the TRAP study
Presenter: Charlotte Stroes
Session: Poster Display session 2
Resources:
Abstract
5403 - Interim analysis of a phase II trial of perioperative chemotherapy plus avelumab in esophagogastric and gastric adenocarcinoma
Presenter: Thierry Alcindor
Session: Poster Display session 2
Resources:
Abstract
591 - Evaluation of the introduction of primary G-CSF prophylaxis to the FLOT chemotherapy regimen.
Presenter: Kelly-Marie Crampton
Session: Poster Display session 2
Resources:
Abstract
1402 - Subgroup analyses of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with 2 and 4 courses of cisplatin/S-1 (CS) and docetaxel/cisplatin/S-1 (DCS) as neoadjuvant chemotherapy for locally advanced gastric cancer
Presenter: Tsutomu Hayashi
Session: Poster Display session 2
Resources:
Abstract
3743 - HER2 Copy Number as Predictor of Disease-Free Survival in HER2-Positive Resectable Gastric Cancer
Presenter: Zimin Liu
Session: Poster Display session 2
Resources:
Abstract
2032 - Effect of neoadjuvant chemotherapy on the Programmed Death-1 pathway in esophageal and gastric cancer
Presenter: Maria Svensson
Session: Poster Display session 2
Resources:
Abstract
4304 - A user-friendly nomogram to predict relapse-free survival (RFS) in western patients with resected gastric cancer (GC)
Presenter: Massimiliano Salati
Session: Poster Display session 2
Resources:
Abstract